CABG surgery clinical trials results

artery grafts versus saphenous vein grafts
CARRPO, 2009
NCT00159991
total arterial revascularization using internal thoracic and radial arteries
versus
conventional revascularization using left internal thoracic artery and vein grafts
patients with multivessel or isolated left main disease referred for elective or urgent CABGopen
Follow-up duration: 11.1 months
aspirin versus placebo
McEnany, 1982
aspirin 1200
versus
placebo
patients undergoing coronary bypass graftingdouble blind
Follow-up duration: 22m
Lorenz, 1984
aspirin 100 mg/d
versus
placebo
patients undergoing CABGdouble blind
Follow-up duration: 4m
GESIC (aspirin), 1990
aspirin 150 mg daily
versus
placebo
patients undergoing CABGdouble blind
Follow-up duration: 28d
Sydney, 1991
aspirin 324 mg daily
versus
placebo
patients undergoing CABGdouble blind
Follow-up duration: 12m
Hockings, 1993
aspirin 100
versus
placebo
patients undergoing CABGdouble blind
Follow-up duration: 6m
aspirin + dipyridamol versus control
Pantely, 1979
aspirin 325 mg three times a day + dipyridamole 75 mg three times a day
versus
control
patients undergoing aortocoronary saphenous-vein bypass-graft surgeryopen
Follow-up duration: 6m
Brussels, 1987
aspirin 200 + dipiridamol 400 (H)
versus

Follow-up duration: 12m
Czech, 1986
aspirin 1000 + dipiridamol 225
versus
control (no medication)
Patients with aortocoronary bypasses with intraoperative blood flow rates of 40 ml/min or less open
Follow-up duration: 12m
Des Moines, 1980
aspirin 20 + dipiridamol 100
versus

Follow-up duration: 12m
aspirin + dipyridamol versus placebo
GESIC (aspirin+dipyridamol), 1990
aspirin 50 mg + dipyridamole 75mg 3 times daily
versus
placebo
patients undergoing CABG double blind
Follow-up duration: 28d
Spain
Brooks, 1985
aspirin 990 mg and dipyridamole 225 mg daily
versus
placebo
patients undergoing coronary bypass graftingdouble blind
Follow-up duration: 12m
Mayo-A, 1984
aspirin 975 + dipiridamol 225
versus
placebo
patients undergoing coronary bypass graftingdouble blind
Follow-up duration: 12m
Wadsworth, 1985
aspirin 975 mg/d + dipiridamol 225 mg/d, aspirin 975 mg/d
versus
placebo
coronary bypass patients double blind
Follow-up duration: 12m
Basel, 1989
aspirin 50 + dipiridamol 400
versus
placebo
patients who had aortocoronary vein bypass surgery double blind
Follow-up duration: 9m
Leeds-B, 1985
aspirin 990 + dipiridamol 225 (W)
versus
placebo
patients undergoing aorta-coronary bypass grafting for disabling anginadouble blind
Follow-up duration: 6m
Thaulow, 1987
aspirin 975 + dipiridamol 225
versus
placebo
Patients scheduled to receive at least three aortocoronary venous bypass grafts double blind
Follow-up duration: 3m
clopidogrel+aspirin versus aspirin
CASCADE, 2009
NCT00228423
aspirin 162 mg plus clopidogrel 75 mg daily for 1 year
versus
aspirin 162 mg plus placebo daily
patients after CABG involving at least two saphenous vein graftsdouble blind
Follow-up duration: 1 y
dipyridamol versus control
Toronto dipyridamole, 1987
dipiridamol 400
versus
control
patients undergoing elective coronary artery bypass grafting
Follow-up duration: 48h
dipyridamol versus placebo
Ekestrom, 1990
dipiridamol 100 mg orally q.i.d.
versus
placebo
patients undergoing coronary bypass surgerydouble blind
Follow-up duration: 12m
edifoligide pretreatment versus placebo
PREVENT IV, 2005
NCT00042081
saphenous vein grafts pretreated edifoligide
versus
placebo
patients undergoing isolated CABG surgery with at least two vein grafts double blind
Follow-up duration: 12 to 18 months
US
off-pump versus on-pump
Al-Ruzzeh b, 2006
off-pump
versus
coronary artery bypass grafting surgery using cardiopulmonary bypass
patients requiring primary isolated coronary artery bypass grafting surgeryopen with blinded assessment
Follow-up duration: 6 months
UK
Alwan, 2004
beating heart revascularization
versus
arrested heart revascularization
patients undergoing CABGopen
Follow-up duration: In-hospital/30-day mortality
Ascione, 2006
off-pump coronary artery bypass grafting
versus
artery bypass grafting with cardiopulmonary bypass
patient undergoing CABGopen
Follow-up duration: In-hospital
Ascionee, 2005
off-pump CABG
versus
on-pump CABG
patient undergoing CABGopen
Follow-up duration: In-hospital
Baker, 2001
off pump surgery using the Octopus II stabilizing system
versus
conventional CABG cardiopulmonary bypass
elective patients requiring surgery for double or triple vessel disease open
BBS (Moller), 2010
NCT00120991
off-pump CABG
versus
on-pump CABG
patients > 54 years of age with three-vessel coronary artery disease with EuroSCORE of 5-16 undergoing elective or sub-acute coronary artery bypass graftingopen blind assessor
Follow-up duration: 30 days
BHACAS I (Ascione), 1999
off-pump
versus
on-pump
cardiac surgery candidates open with blinded assessment
Follow-up duration: 25 months
BHACAS II (Angelini), 2002
off-pump
versus
on-pump
patients with myocardial infarction in the past month or who required grafting of the circumflex artery distal to the first obtuse marginal branchopen with blinded assessment
Follow-up duration: 13.7 months
Caputo, 2002
beating heart surgery (off-pump)
versus
conventional CABG with cardiopulmonary bypass
patients undergoing coronary artery bypass graftingopen
Follow-up duration: In-hospital
Carrier, 2003
off-pump CABG
versus
on-pump CABG
high-risk patientsopen
Follow-up duration: In-hospital/30-day mortality
Covino, 2001

versus
open
Follow-up duration: In-hospital
Czerny, 2000

versus
open
Czerny b, 2001

versus
open
Diegeler, 2000
coronary artery bypass operation without cardiopulmonary bypass (off-pump CABG)
versus
conventional coronary artery bypass operation using cardiopulmonary bypass
cardiac surgery candidates open
Follow-up duration: In-hospital
DOORS, 2009
NCT00123981
Off-Pump Coronary Artery Bypass Grafting
versus
on-pump CABG
elderly patientsopen
Follow-up duration: 30 days
Dorman, 2004

versus
open
Gasz, 2004

versus
open
Gerola, 2001
off-pump coronary artery bypass
versus
on-pump CABG
low-risk patients undergoing CABGopen
Follow-up duration: In-hospital/30-day mortality
Gu, 1998
minimally invasive coronary artery bypass grafting
versus
conventional coronary artery bypass grafting with cardiopulmonary bypass
patients with isolated stenosis of the left anterior descending coronary arteryopen
Follow-up duration: In-hospital
Guler, 2001

versus
open
Gulielmos, 1999
off-pump coronary artery bypass with median sternotomy or off-pump procedure and lateral minithoracotomy
versus
conventional technique or lateral minithoracotomy and cardiopulmonary bypass
patients with coronary artery single-vessel disease open
Follow-up duration: 3 months
Jares, 2006
off-pump CABG
versus
on-pump CABG
patients scheduled for coronary bypass grafting open
Follow-up duration: 24 h
Khan, 2004
off-pump CABG
versus
conventional "on-pump" surgery
patient undergoing CABGopen
Follow-up duration: 3 months
Kobayashi, 2005
off-pump CABG
versus
on-pump CABG
patients referred for elective primary CABGopen
Follow-up duration: 30 days
Kunes, 2007
off-pump CABG
versus
on-pump CABG
patient undergoing CABGopen
Follow-up duration: 7 days
Lee, 2003
off-pump CABG
versus
conventional on-pump CABG
patients undergoing CABGopen
Legare, 2004
NCT00216957
off-pump CABG
versus
on-pump CABG
patients undergoing CABGopen
Follow-up duration: 3.8 years
Lingaas, 2003
off-pump CABG
versus
on-pump CABG
patient undergoing CABGopen
Follow-up duration: 12 months
Matata, 2000
off-pump
versus
on-pump
cardiac surgery candidates open
Follow-up duration: In-hospital
Michaux, 2006
off-pump CABG
versus
on-pump CABG
patients scheduled for elective coronary artery bypass surgeryopen
Follow-up duration: 30 days
Motallebzadeh, 2004
off-pump CABG
versus
on-pump CABG
patients admitted for CABG open
Follow-up duration: In-hospital
Motallebzadeh b, 2006
off-pump CABG
versus
on-pump CABG
patients admitted for elective coronary artery bypass graft surgery open
Follow-up duration: 6 months
Muneretto, 2003

versus
open
Niranjan, 2006
off-pump CABG with or without cell saver blood transfusion
versus
on-pump CABG with or without cell saver blood transfusion
patient undergoing CABGopen
Follow-up duration: In-hospital
OCTOPUS (van Dijk), 2002
off-pump surgery
versus
on-pump surgery
patients with predominantly single- or double-vessel coronary diseaseopen with blinded assessment
Follow-up duration: 5 years
the Netherlands
Ozkara, 2007
off-pump CABG
versus
on-pump CABG
patients admitted for elective CABG open
Follow-up duration: In-hospital
Paparella, 2006
off-pump CABG
versus
on-pump CABG
patient undergoing CABGopen
Follow-up duration: In-hospital
Parolari, 2003

versus
open
Parolari b, 2003

versus
open
Penttila, 2001
off-pump CABG
versus
on-pump CABG
patients requiring CABGopen
Follow-up duration: In-hospital
PRAGUE 4 (Widimsky), 2004
off pump
versus
on pump
cardiac surgery candidates open
Follow-up duration: 1 y
PROMISS (Uva), 2010
off-pump
versus
on-pump
patients between 30 and 90 years of age with multi-vessel coronary artery disease undergoing CABG with at least three distal coronary anastomosesopen
Follow-up duration: 5 weeks (498 days)
Puskas, 2004

versus
open
Raja b, 2003
on-pump CABG
versus
off-pump CABG
patients undergoing CABGopen
Follow-up duration: In-hospital
ROOBY (Shroyer), 2009
NCT00032630
off-pump CABG
versus
on-pump CABG
patients scheduled for urgent or elective coronary bypass surgery open
Follow-up duration: 1 mo (1y)
USA
Sahlman, 2003

versus
open
Selvanayagam, 2004
off-pump CABG
versus
on-pump CABG
patients undergoing multivessel CABG open
Follow-up duration: In-hospital
SMART (Staton), 2003
off-pump coronary artery bypass
versus
CABG with cardiopulmonary bypass
patients unselected for coronary anatomy, ventricular function, or comorbidities open with blinded assessment
Follow-up duration: 12 months
US
Syed, 2004

versus
open
Tang, 2002

versus
open
Tatoulis, 2006
off-pump CABG
versus
on-pump CABG
candidates for elective CABGopen
Follow-up duration: 30 days
Vedin, 2006
off-pump CABG
versus
on-pump CABG
patients between 50 and 80 years with stable angina pectoris, ejection fraction >30%, serum creatinine <150 micromol/l, and lack of tight main stem stenosis open
Velisaris, 2003

versus
open
Vural, 1995

versus
open
Wan, 2004

versus
open
Wandschneider, 2000

versus
open
Zamvar, 2002
off-pump CABG
versus
on-pump CABG
patients undergoing coronary artery bypass graft surgery for triple vessel disease open
Follow-up duration: 10 weeks
UK
preoperative atorvastatin versus placebo
Chello et al., 2006
preoperative atorvastatin 20 mg/d, started 3 wks before surgery
versus
placebo
elective CABGdouble blind
Follow-up duration: 7 days
Patti et al., 2006
preoperative atorvastatin 40 mg/d, starting 7 days before operation
versus
placebo
patients undergoing elective cardiac surgery with cardiopulmonary bypass, without previous statin treatment or history of AFdouble blind
Follow-up duration: 30 days
preoperative simvastatin versus no treatment
Christenson, 1999
preoperative simvastatin 20 mg/d, stated 4 weeks before surgery
versus
no statins
patients with hypercholesterolemia (total cholesterol > or =6.2 mmol/l) planned for CABG
Follow-up duration: 7 days
radial artery grafts versus saphenous vein grafts
RAPS (Desai), 2004
NCT00187356
group 1
versus
group 2
patients undergoing bypass of the anterior circulationopen
Follow-up duration: 12 months
Canada, New Zealand
RSVP, 2008
NCT00139399
radial artery grafted to a stenosed branch of the native left circumflex coronary artery
versus
saphenous vein grafted to a stenosed branch of the native left circumflex coronary artery
patient undergoing CABG for a stenosed branch of the native left circumflex coronary arteryopen
Follow-up duration: 5 ans
England
Gaudino (radial A), 2005
radial artery on the first obtuse marginal artery
versus
great saphenous vein graft on the first obtuse marginal artery
coronary artery bypass patients with previous in-stent restenosis (n=60) or not (n=60)open
Follow-up duration: 52 months
Italy
VA CABG, 2010
NCT00054847
radial artery graft
versus
saphenous vein graft
patients with stable coronary artery disease open
Follow-up duration: 1 year (5y)
USA
remote ischemic preconditioning versus control
Cheung, 2006
remote ischemic preconditioning
versus
control
children undergoing cardiac surgery for repair of congenital heart defects open
Gunaydin, 2000
remote ischemic preconditioning
versus
control
patients undergoing coronary artery surgeryopen
Hausenloy, 2007
NCT00397163
remote ischemic preconditioning
versus
patients undergoing elective coronary artery bypass graft surgerysingle blind
remote ischemic preconditioning versus no RIPC
Ali, 2007
remote ischemic preconditioningm
versus
without RIPC
patients undergoing elective open abdominal aortic aneurysm repairopen
right internal thoracic artery grafts versus saphenous vein grafts
Gaudino (RITA), 2005
right internal thoracic artery on the first obtuse marginal artery
versus
great saphenous vein graft on the first obtuse marginal artery
coronary artery bypass patients with previous in-stent restenosis (n=60) or not (n=60) open
Follow-up duration: 52 months
Italy
sulfinpyrazone versus placebo
Baur, 1982
sulfinpyrazone 800 mg/day
versus
placebo
patients undergoing CABGdouble blind
Follow-up duration: 10d
sulotroban versus control
German sulotroban, 1989
ST
versus

Follow-up duration: 21d
ticlopidine versus control
Zurich, 1982
ticlopidine 500 (NC)
versus

Follow-up duration: 3m
Knudsen-B, 1983
ticlopidine 500
versus

Follow-up duration: 6m
Romeo, 1983
ticlopidine 500
versus

Follow-up duration: 3m (12m)
Kohn, 1990
ticlopidine 500
versus

Follow-up duration: 14d
ticlopidine versus placebo
Liège-I, 1984
ticlopidine 250 mg twice daily
versus
placebo
patients undergoing aortocoronary bypass graft proceduresdouble blind
Follow-up duration: 3m
Liège-II, 1987
ticlopidine 250 mg twice daily
versus
placebo
patients undergoing venous coronary artery bypass grafting double blind
Follow-up duration: 12m
various versus placebo
Guiteras, 1989
aspirin 150 + dipiridamol 225, dipiridamol 225 + trifusal 900
versus
placebo
patients undergoing coronary bypass graftingdouble blind
Follow-up duration: 7m
VA Co-op CABG, 1988
aspirin 325 daily, aspirin 325 three times daily, sulfinpyrazone, aspirin plus dipyridamole (325 mg and 75 mg, respectively, three times daily)
versus
placebo
patients undergoing CABGdouble blind
Follow-up duration: 12m